Applied Biosafety最新文献

{"title":"The Use of Temperature and Pressure Data Loggers to Validate the Steam Sterilization of Category A Clinical Waste.","authors":"Jade Flinn,&nbsp;Andrew Michalek,&nbsp;Lindsay Bow,&nbsp;Noreen A Hynes,&nbsp;Donald Philpot,&nbsp;Brian T Garibaldi","doi":"10.1089/apb.2022.0003","DOIUrl":"https://doi.org/10.1089/apb.2022.0003","url":null,"abstract":"<p><strong>Introduction: </strong>Over the past decade, there have been outbreaks associated with high consequence infectious diseases such as Ebola virus disease, Lassa fever, and Monkeypox. The proper handling of clinical waste from patients infected with such pathogens is critical to ensure healthcare personnel and community safety.</p><p><strong>Methods: </strong>Mock clinical waste bags were created to simulate four distinct waste streams: personal protective equipment (PPE), dry linens, wet linens, and solidified liquids. Pressure and temperature data loggers were buried in the middle of simulated waste loads to record time at a sterilization temperature of 132°C (270°F) to reduce sterilization time. We also validated super rapid biological indicators (BIs) by embedding standard BIs (48 h), rapid BIs (3 h), and super rapid BIs (24 min) within each load. Cycles were validated over a 2-day period, using a total of 36 simulated waste bags (6 bags each for PPE, dry linen, and wet linen, and 18 bags for solidified liquids).</p><p><strong>Results: </strong>All waste bags achieved the target sterilization temperature, all BIs passed and cycle times were substantially decreased. For PPE waste processing, an estimated 15 h was saved for a 24-h period.</p><p><strong>Discussion: </strong>Default factory settings are inadequate to disinfect Category A clinical waste. Reliance on autoclave temperature readings may overestimate time at goal sterilization temperature for actual waste loads.</p><p><strong>Conclusions: </strong>The data provided by within bag data loggers and BIs allow for the optimization of autoclave parameters to increase throughput and enhance staff safety.</p>","PeriodicalId":7962,"journal":{"name":"Applied Biosafety","volume":"27 2","pages":"106-115"},"PeriodicalIF":1.5,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908284/pdf/apb.2022.0003.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9550356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Established Competency Categories of the Biosafety, Infection Prevention, and Public Health Professions: A Guide for Addressing Needed Professional Development Training for the Current and Next Pandemic.","authors":"Robert J Emery,&nbsp;Scott J Patlovich,&nbsp;Kristin G King,&nbsp;John M Lowe,&nbsp;Janelle Rios","doi":"10.1089/apb.2022.0002","DOIUrl":"https://doi.org/10.1089/apb.2022.0002","url":null,"abstract":"<p><p>A recent series of widespread infectious disease outbreaks has highlighted commonalities and differences between three key professions that operate on the front lines of response in support of research and/or direct healthcare providers: biosafety, infection prevention, and public health. This assessment, which builds upon previous study by the authors, examines the stated professional competency categories for these three areas, highlighting similarities and differences. This assessment is important as these professions are being drawn together in an operational environment driven by the current pandemic and inevitably future disease outbreaks. Cross-training opportunities for the various professions are proposed.</p>","PeriodicalId":7962,"journal":{"name":"Applied Biosafety","volume":"27 2","pages":"53-57"},"PeriodicalIF":1.5,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908272/pdf/apb.2022.0002.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9556753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monitoring Laboratory Occupational Exposures to <i>Burkholderia pseudomallei</i>.","authors":"LaTonya A Clay, Kurtis W Straub, Sherry L Adrianos, Jonathan Daniels, Jerry L Blackwell, Lonnie T Bryant, Von McClee, Judith A Green, Samuel S Edwin","doi":"10.1089/apb.2021.0039","DOIUrl":"10.1089/apb.2021.0039","url":null,"abstract":"<p><strong>Background: </strong><i>Burkholderia pseudomallei</i> is a Tier 1 overlap select agent and subject to the select agent regulations (42 CFR §73 and 9 CFR §121). It is a gram-negative, motile, soil saprophyte, and the etiologic agent of melioidosis. <i>B. pseudomallei</i> infection can produce systemic illness and can be fatal in the absence of appropriate treatment. Laboratory exposures involving this organism may occur when appropriate containment measures are not employed. Current disease treatment inadequacies and the risk factors associated with melioidosis make this an agent of primary concern in research, commercial, and clinical laboratory environments.</p><p><strong>Results: </strong>This study presents data reported to Centers for Disease Control and Prevention (CDC), Division of Select Agents and Toxins for releases involving <i>B. pseudomallei</i> in 2017-2019 that occurred in Biosafety Level (BSL)-2 and BSL-3 laboratories. Fifty-one Animal and Plant Health Inspection Service (APHIS)/CDC Form 3 release reports led to the medical surveillance of 275 individuals. Entities offered post-exposure prophylaxis to ∼76% of the individuals impacted in the presented events.</p><p><strong>Summary: </strong>Laboratory safety can be improved by implementing appropriate safety precautions to minimize exposures. Most of the incidents discussed in this evidence-based report occurred during work conducted in the absence of primary containment. None of the releases resulted in illness, death, or transmission to or among workers, nor was there transmission outside of a laboratory into the surrounding environment or community. Effective risk assessment and management strategies coupled with standard and special microbiological policies and procedures can result in reduced exposures and improved safety at facilities.</p>","PeriodicalId":7962,"journal":{"name":"Applied Biosafety","volume":"27 2","pages":"84-91"},"PeriodicalIF":0.5,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908285/pdf/apb.2021.0039.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9556750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hydrogen Peroxide Vapor Decontamination of Hazard Group 3 Bacteria and Viruses in a Biosafety Level 3 Laboratory.","authors":"Charlotte Falaise, Cécile Bouvattier, Guilhem Larigauderie, Valérie Lafontaine, Laurent Berchebru, Audrey Marangon, Valérie Vaude-Lauthier, Françoise Raynaud, Laurent Taysse","doi":"10.1089/apb.2021.0022","DOIUrl":"10.1089/apb.2021.0022","url":null,"abstract":"<p><strong>Aim: </strong>This study aimed to validate the efficacy of hydrogen peroxide vapor (HPV) decontamination technology set up in a biosafety level 3 (BSL-3) laboratory on surrogates and hazard group 3 (HG3) agents.</p><p><strong>Methods and results: </strong>The HPV decontamination system (Bioquell) was assessed with both qualitative and quantitative methods on (1) spore surrogates (<i>Geobacillus stearothermophilus</i>, <i>Bacillus atrophaeus</i>, and <i>Bacillus thuringiensis</i>) in the BSL-3 laboratory and in the material airlock and on (2) HG3 agents (<i>Bacillus anthracis;</i> SARS-CoV-2, Venezuelan equine encephalitis virus [VEE], and Vaccinia virus) in the BSL-3 laboratory. Other HG3 bacteria likely to be handled in the BSL-3 laboratory (<i>Yersinia pestis</i>, <i>Burkholderia mallei</i>, <i>Brucella melitensis</i>, and <i>Francisella tularensis</i>) were excluded from the HPV decontamination assays as preliminary viability tests demonstrated the total inactivation of these agents after 48 h drying on different materials.</p><p><strong>Conclusions: </strong>The efficacy of HPV decontamination was validated with a reduction in viability of 5-7 log₁₀ for the spores (surrogates and <i>B. anthracis</i>), and for the enveloped RNA viruses. Vaccinia showed a higher resistance to the decontamination process, being dependent on the biological indicator location in the BSL-3 laboratory.</p>","PeriodicalId":7962,"journal":{"name":"Applied Biosafety","volume":"27 1","pages":"15-22"},"PeriodicalIF":0.5,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402245/pdf/apb.2021.0022.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10869236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing High-Reliability Organization Principles at Biological Diagnostic Laboratories: Case Study at National Institute of Health, Islamabad.","authors":"Sana Tamim,&nbsp;Syeda Shazia Adeel,&nbsp;Tim Trevan,&nbsp;Aamer Ikram,&nbsp;Nadira Jadoon,&nbsp;Ayesha Zaman,&nbsp;Rashid Mehmood,&nbsp;Qazi Muhammad Ashfaq,&nbsp;Atifa Mushtaq,&nbsp;Maria Shaukat,&nbsp;Mehak Nimra,&nbsp;Saima Hamid,&nbsp;Iqra Shabbir","doi":"10.1089/apb.2021.0011","DOIUrl":"https://doi.org/10.1089/apb.2021.0011","url":null,"abstract":"<p><strong>Introduction: </strong>Healthcare organizations are complex systems where healthcare professionals, patients, biological materials, and equipment constantly interact and provide feedback with highly consequential outcomes. These are the characteristics of a complex adaptive system. Healthcare delivery requires coordination but it necessarily relies on delegation of essential functions. It is thus essential to have an engaged workforce to ensure optimal outcomes for patients. Thus human performance factors play a key role in ensuring both the presence of excellent healthcare provision and the absence of outcomes that must be avoided-\"never events.\"</p><p><strong>Methods: </strong>The commitment of management was a precondition for the implementation of the high-reliability organization (HRO) principles. A team from middle management was engaged and provided with appropriate management tools for identifying, prioritizing, assessing, and applying solutions for the safety concern in their operating systems.</p><p><strong>Results: </strong>This article documents efforts at the National Institute of Health (NIH) to adapt the principles of HROs to diagnostic laboratories and vaccine production facilities at its campus in Islamabad, Pakistan, and seeks to draw some lessons for how this approach can be usefully replicated in such facilities elsewhere.</p><p><strong>Conclusion: </strong>Public health institutes such as NIH deliver vital products and services that are inherently risky to produce, where the consequence of failure can be catastrophic. Adopting the HRO principles is an approach to improving not just safety, but also the overall organizational performance in any setting, including low-resource settings, and can serve as an implementable process for other institutions.</p>","PeriodicalId":7962,"journal":{"name":"Applied Biosafety","volume":"27 1","pages":"33-41"},"PeriodicalIF":1.5,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402247/pdf/apb.2021.0011.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10869238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biosafety Capacity Building During the COVID-19 Pandemic: Results, Insights, and Lessons Learned from an Online Approach in the Philippines.","authors":"Rohani Cena-Navarro,&nbsp;Rodel Jonathan Vitor,&nbsp;Reynand Jay Canoy,&nbsp;Angelo Dela Tonga,&nbsp;Gianne Eduard Ulanday,&nbsp;Mary Rose Claire Silva,&nbsp;Raul V Destura","doi":"10.1089/apb.2021.0021","DOIUrl":"https://doi.org/10.1089/apb.2021.0021","url":null,"abstract":"<p><strong>Introduction: </strong>COVID-19 diagnosis was one of the most pressing needs during the early stages of the pandemic. Its entire procedure has inherent biosafety risks that if not properly managed and mitigated can be life threatening. Cognizant of this vital aspect, the Department of Health (DOH) imposed a biosafety training requirement to all laboratories and institutions before they could perform COVID-19 diagnostic testing. But with the mandatory lockdown, conventional face-to-face training could not be conducted. To address this need, the Biosafety Education and Awareness Training COVID-19 Online Program was offered by the National Training Center for Biosafety and Biosecurity of the University of the Philippines Manila.</p><p><strong>Methods and materials: </strong>This online training program implemented a distance learning approach made available through the Canvas Learning Management System. It consisted of seven modules on biosafety that were sufficient enough to capacitate the participants with information for them to effectively implement a biorisk management system. The participants were evaluated based on quiz, examination, and case analysis. Certificates of completion were awarded to participants who passed all evaluation methods.</p><p><strong>Results: </strong>A total of 3371 trainees from various medical professions passed and obtained the certificate. This resulted in >100 DOH-accredited COVID-19 testing laboratories by the end of 2020.</p><p><strong>Discussion and conclusion: </strong>The online availability of this program proved to be an effective innovative solution to a unique problem. Therefore, this training program demonstrated that biosafety training can be effectively conducted online and in a distance learning approach.</p>","PeriodicalId":7962,"journal":{"name":"Applied Biosafety","volume":"27 1","pages":"42-50"},"PeriodicalIF":1.5,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402248/pdf/apb.2021.0021.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10869235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledgment of Reviewers 2021.","authors":"","doi":"10.1089/apb.2021.29007.ack","DOIUrl":"https://doi.org/10.1089/apb.2021.29007.ack","url":null,"abstract":"","PeriodicalId":7962,"journal":{"name":"Applied Biosafety","volume":"27 1","pages":"51"},"PeriodicalIF":1.5,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917310/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9297197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reducing Strategic Forbearance under the CARES Act: an Experimental Approach Utilizing Recourse Attestation.","authors":"Jackson T Anderson, David M Harrison, Michael J Seiler","doi":"10.1007/s11146-021-09842-4","DOIUrl":"10.1007/s11146-021-09842-4","url":null,"abstract":"<p><p>The Coronavirus Aid, Relief, and Economic Security (CARES) Act was passed in response to both the global pandemic's immediate negative and expected long-lasting impacts on the economy. Under the Act, mortgage borrowers are allowed to cease making payments if their income was negatively impacted by Covid-19. Importantly, borrowers were not required to demonstrate proof of impaction, either currently or retrospectively. Exploring the economic implications of this policy, this study uses an experimental design to first identify strategic forbearance incidence, and then to quantify where the forborne mortgage payment dollars were spent. Our results suggest strategic mortgage forbearance can be significantly reduced, saving taxpayers billions of dollars in potential losses, simply by requiring a 1-page attestation with lender recourse for borrowers wishing to engage in COVID-19 related mortgage payment cessation programs. Additionally, we demonstrate the use of these forborne mortgage payments range from enhancing the financial safety net for distressed borrowers by increasing precautionary savings, to buying necessities, to equity investing and debt consolidation.</p>","PeriodicalId":7962,"journal":{"name":"Applied Biosafety","volume":"16 1","pages":"230-260"},"PeriodicalIF":0.5,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87573611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Changing World in Gene Therapy Research: Exciting Opportunities for Medical Advancement and Biosafety Challenges.","authors":"Daniel Eisenman, Shaun Debold, James Riddle","doi":"10.1089/apb.2021.0020","DOIUrl":"10.1089/apb.2021.0020","url":null,"abstract":"<p><p><b>Introduction:</b> We previously reported on the United States' regulatory environment evolving to accommodate an emerging boom in gene therapy research. Several important developments have transpired in the 2 years since that article was published, including the coronavirus disease 2019 (COVID-19) pandemic and the drive for large-scale testing of vaccines containing recombinant or synthetic nucleic acid molecules. This report highlights key developments in the field with a focus on biosafety and issues of note to biosafety professionals with responsibilities over clinical research. <b>Discussion:</b> We provide guidance for performing risk assessments on the currently approved gene therapy products as well as the most utilized types of investigational products in clinical trials. Areas of focus include the prominent approaches utilized in the three major areas of research: oncology, infectious diseases, and rare diseases. <b>Conclusion:</b> The COVID-19 pandemic has created several opportunities for continued growth in gene therapy. National vaccination campaigns will result in greater public acceptance of gene therapy research. Technological advancements that made the vaccine race possible will spur the next generation of research. Advancements born in the developed world set the stage for the creation of therapeutics to treat greater numbers in the developing world and have the potential for massive benefits to global public health. Biosafety professionals and Institutional Biosafety Committees play key roles in contributing to the safe evidence-based advancement of gene therapy research. Biosafety professionals responsible for clinical research oversight must be aware of emerging technologies and their associated risks to support the safe and ethical conduct of research.</p>","PeriodicalId":7962,"journal":{"name":"Applied Biosafety","volume":"26 4","pages":"179-192"},"PeriodicalIF":0.5,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33443272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of the Biosafety and Biosecurity Landscape in the Philippines and the Development of the National Biorisk Management Framework.","authors":"Raul V Destura, Hilton Y Lam, Rohani C Navarro, Jaifred Christian F Lopez, Reneepearl Kim P Sales, Ma Ida Faye A Gomez, Angelo Dela Tonga, Gianne Eduard Ulanday","doi":"10.1089/apb.20.0070","DOIUrl":"10.1089/apb.20.0070","url":null,"abstract":"<p><p><b>Introduction:</b> The emergence of biological threats that can potentially affect millions emphasizes the need to develop a policy framework in the Philippines that can mount an adequate and well-coordinated response. The objective of the study was to assess, strengthen, and harmonize efforts in biorisk management through the development of a National Biorisk Management Framework. <b>Methods:</b> The development of the National Biorisk Management Framework was carried out in two phases: (1) assessment of the current biosafety and biosecurity landscape and (2) framework development. <b>Results:</b> This study identified policy gaps in the incorporation of biosafety in course curricula, professional development, and organizational twinning. The desired policy outcomes focus on increasing the capacity and quality of facilities, and the development of the biosafety officer profession. The tabletop exercises revealed weak implementation of existing protocols and unclear coordination mechanisms for emergency response. Based on these, a framework was drafted composed of eight key areas in biosafety and biosecurity, and four key contexts in risk reduction and management. <b>Discussion and Conclusion:</b> Reforms in biosafety and biosecurity policies are expected to improve coordination, ensure sustainability, capacitate facilities, and professionalize biosafety officers. Because of the complexity of reforms necessary, success will require a consistent and coherent policy framework that (1) provides well-coordinated mechanisms toward harmonized risk reduction and management, (2) establishes and enforces guidelines on biosafety, biosecurity, and biorisk management, (3) regulates facilities essential for occupational safety and public health, and (4) is financed by the General Appropriations Act as part of the national budget.</p>","PeriodicalId":7962,"journal":{"name":"Applied Biosafety","volume":"26 4","pages":"232-244"},"PeriodicalIF":0.5,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/36/apb.20.0070.PMC9134340.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33443848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}